1. Home
  2. KPTI vs INVE Comparison

KPTI vs INVE Comparison

Compare KPTI & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • INVE
  • Stock Information
  • Founded
  • KPTI 2008
  • INVE 1990
  • Country
  • KPTI United States
  • INVE United States
  • Employees
  • KPTI N/A
  • INVE N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • INVE Computer peripheral equipment
  • Sector
  • KPTI Health Care
  • INVE Technology
  • Exchange
  • KPTI Nasdaq
  • INVE Nasdaq
  • Market Cap
  • KPTI 81.1M
  • INVE 86.5M
  • IPO Year
  • KPTI 2013
  • INVE 1997
  • Fundamental
  • Price
  • KPTI $0.65
  • INVE $3.64
  • Analyst Decision
  • KPTI Strong Buy
  • INVE Strong Buy
  • Analyst Count
  • KPTI 4
  • INVE 2
  • Target Price
  • KPTI $5.00
  • INVE $7.25
  • AVG Volume (30 Days)
  • KPTI 694.6K
  • INVE 38.4K
  • Earning Date
  • KPTI 02-27-2025
  • INVE 03-11-2025
  • Dividend Yield
  • KPTI N/A
  • INVE N/A
  • EPS Growth
  • KPTI N/A
  • INVE N/A
  • EPS
  • KPTI N/A
  • INVE 3.10
  • Revenue
  • KPTI $148,442,000.00
  • INVE $104,217,000.00
  • Revenue This Year
  • KPTI $5.47
  • INVE N/A
  • Revenue Next Year
  • KPTI $6.33
  • INVE N/A
  • P/E Ratio
  • KPTI N/A
  • INVE $1.15
  • Revenue Growth
  • KPTI 1.77
  • INVE 70.57
  • 52 Week Low
  • KPTI $0.58
  • INVE $2.95
  • 52 Week High
  • KPTI $1.70
  • INVE $9.24
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • INVE 43.25
  • Support Level
  • KPTI $0.60
  • INVE $3.50
  • Resistance Level
  • KPTI $0.70
  • INVE $3.82
  • Average True Range (ATR)
  • KPTI 0.05
  • INVE 0.18
  • MACD
  • KPTI -0.00
  • INVE -0.01
  • Stochastic Oscillator
  • KPTI 46.61
  • INVE 21.82

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About INVE Identiv Inc.

Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has two reportable segments namely the Premises segment which includes solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. Its Identity segment includes products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the IoT with RFID. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific. The company derives the majority of revenue from the Identity segment.

Share on Social Networks: